Conference Reports for NATAP

The Liver Meeting AASLD 2025 Washington, D.C. November 7-11, 2025 Back

Rates of functional cure in participants with chronic hepatitis B virus infection treated with bepirovirsen: B-Well Phase 3 trials end of study results       AASLD 2026 Denver   AASLD: Bepirovirsen B-Well Phase 3 trials: Predicting functional cure rates based upon hepatitis B surface antigen at Week 12 - (11/07/26)   AASLD: Bepirovirsen B-Well Phase 3 trials: Predicting functional cure rates based upon hepatitis B surface antigen at Week 12 - (11/07/26)